Stem cell therapy for Alzheimer's disease: hype or hope?

Liu, Alan King Lun
January 2013
Bioscience Horizons: The National Undergraduate Research Journal;Jan2013, Vol. 6, p1
Academic Journal
Alzheimer's disease (AD) is the most common neurodegenerative disease affecting millions of people in the world. Cognitive impairments such as progressive memory loss are devastating manifestations from this disease. Current pharmacological treatment has limited efficacy and only provides symptomatic relief without long-term cure. As a result, cell-replacement therapy using stem cells is an emerging potential treatment to AD. In the last decade, there have been animal trials using stem cells to treat and modulate cognitive impairment in AD models via three different mechanisms—replacing the damaged or dead cholinergic neurons; protecting neurons by reducing toxic amyloid protein aggregates or insoluble tau neurofibrillary tangles and promoting neurogenesis in hippocampus by neurotrophic secretions from stem cells. All of the trials showed promising results and improved our understandings about the mechanism of dementia in AD. With the continued improvement in safety profile of stem cell therapy and the creation of a better animal AD model in which to test them, it is feasible that stem cells could be trialled in humans for AD treatment in the next 5–10 years.


Related Articles

  • Exposure to Mobile Phone Radiation Opens New Horizons in Alzheimer's Disease Treatment. Mortazavi, S. A. R.; Shojaei-Fard, M. B.; Haghani, M.; Shokrpour, N.; Mortazavi, S. M. J. // Journal of Biomedical Physics & Engineering;Sep2013, Vol. 3 Issue 3, p109 

    Alzheimer's disease, the most common type of dementia and a progressive neurodegenerative disease, occurs when the nerve cells in the brain die. Although there are medications that can help delay the development of Alzheimer's disease, there is currently no cure for this disease. Exposure to...

  • Aberrant Wnt signaling pathway in medial temporal lobe structures of Alzheimer's disease. Riise, Jesper; Plath, Niels; Pakkenberg, Bente; Parachikova, Anna // Journal of Neural Transmission;Sep2015, Vol. 122 Issue 9, p1303 

    Cognitive decline is a cardinal feature of Alzheimer's disease (AD) predominantly linked to synaptic failure, disrupted network connectivity and neurodegeneration. A large body of evidence associates the Wnt pathway with synaptic modulation and cognitive processes, suggesting a potential role...

  • Prefibrillar Tau Oligomers in Mild Cognitive Impairment and Alzheimer's Disease. Mufson, Elliott J.; Ward, Sarah; Binder, Lester // Neurodegenerative Diseases;Jan2014, Vol. 13 Issue 2/3, p151 

    Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of extracellular amyloid-β peptide and intracellular tau. Here, we review data suggesting that prefibrillar tau oligomers mediate cognitive decline early in the disease....

  • mild cognitive impairment.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1469 

    An encyclopedia entry for "mild cognitive impairment," which refers to a subjectively sensed, and objectively verifiable, loss of memory that may lead to difficulties with word finding, naming, or complex skill execution, is presented.

  • 3 test combo to treat AD? Newman, Elizabeth // McKnight's Long-Term Care News;Jan2013, Vol. 34 Issue 1, p3 

    The article focuses on a study which revealed that diagnostic tests combined with imaging and cerebrospinal fluid biomarkers can help a patient in rapidly recovering from mild cognitive impairment to Alzheimer's disease.

  • Neurorestorative strategies for Alzheimer's disease. Chuyi Huang; Heling Chu; Aikeremujiang Muheremu; Huancong Zuo // Neurology India;Jul/Aug2015, Vol. 63 Issue 4, p583 

    Alzheimer's disease (AD) is characterized by beta-amyloid plaques and neurofibrillary tangles that cause devastating cognitive and memory deficits. AD is known to be associated with neuronal death and synaptic loss. Thus, methods to retard the progression of the disease and to promote...

  • Ablating Adult Neurogenesis in the Rat Has No Effect on Spatial Processing: Evidence from a Novel Pharmacogenetic Model. Groves, James O.; Leslie, Isla; Huang, Guo-Jen; McHugh, Stephen B.; Taylor, Amy; Mott, Richard; Munafò, Marcus; Bannerman, David M.; Flint, Jonathan // PLoS Genetics;Sep2013, Vol. 9 Issue 9, p1 

    The function of adult neurogenesis in the rodent brain remains unclear. Ablation of adult born neurons has yielded conflicting results about emotional and cognitive impairments. One hypothesis is that adult neurogenesis in the hippocampus enables spatial pattern separation, allowing animals to...

  • Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD. Sanfilippo, Cristina; Forlenza, Orestes; Zetterberg, Henrik; Blennow, Kaj // Journal of Neural Transmission;Dec2016, Vol. 123 Issue 12, p1443 

    Synaptic dysfunction is linked to both major depressive disorder (MDD) and Alzheimer's disease (AD). Synapse protein concentrations in cerebrospinal fluid (CSF) may be useful biomarkers to monitor synaptic dysfunction and degeneration that lead to depressive symptoms and AD, respectively. CSF...

  • The brain structural and cognitive basis of odor identification deficits in mild cognitive impairment and Alzheimer's disease. Kjelvik, Grete; Saltvedt, Ingvild; White, Linda R.; Stenumgård, Pål; Sletvold, Olav; Engedal, Knut; Skåtun, Kristina; Lyngvær, Ann Kristin; Steffenach, Hill Aina; Håberg, Asta K. // BMC Neurology;2014, Vol. 14 Issue 1, p2 

    Background The objectives of this study were to explore the relationship between olfactory impairment, cognitive measures, and brain structure volumes in healthy elderly individuals, compared to patients with amnestic mild cognitive impairment (aMCI) or early Alzheimer's disease (AD). The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics